JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

Rare Breast Cancer Types: A Study About Characteristics, Outcomes, and Peculiarities
Received Date : 23 Jul 2020
Accepted Date : 20 Nov 2020
Available Online : 11 Dec 2020
Doi: 10.37047/jos.2020-78231 - Article's Language: EN
J Oncol Sci. 2020;6(3):164-72
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Objective: We aimed to explore different features of rarely seen breast cancer (BC) subtypes, including their stage, molecular subtypes, treatment choices, and prognosis. Material and Methods: We retrospectively screened patients who were diagnosed with BC in our hospital between July 2010 and June 2018. A total of 97 patients who had micropapillary, cribriform, mucinous, papillary, tubular, apocrine, metaplastic, medullary, and myoepithelial subtypes of BC were finally included in the current study.Results: Ninety-four (96.9%) patients were females. Patients with cribriform and mucinous subtypes were in the younger median age of 41 and 45 years, respectively, whereas papillary cases were reported in the oldest median age (64.5 years). Lymph node and TNM stages showed a statistical difference between the subtypes (p=0.029 and p=0.008, respectively). Most of the cribriform (60%), metaplastic (66.7%), and papillary (70%) cases were diagnosed without lymph node involvement. Apocrine (79%) and micropapillary (75%) tumors mostly presented with nodal involvement. While medullary (75%), tubular (66.7%), and cribriform (66.7%) carcinomas were more likely to be diagnosed at stage II, micropapillary (70.8%), and apocrine (62.5%) carcinomas were mostly diagnosed at stage III. Mucinous, tubular, and cribriform tumors were noticed in the luminal group. Medullary, metaplastic, apocrine, and papillary tumors included triple-negative subgroups. HER2-enriched tumors included apocrine (62.5%), medullary (50%), and micropapillary (25%) subtypes. Disease-free survival and overall survival of the patients showed marginal statistical significance according to tumor subtypes (p=0.086, p=0.085, respectively). Conclusion: In this study, we investigated important features, clinical behavior, management, and outcomes of several rare BC subtypes. We opine that the current study may prove instrumental and informative for both daily clinical practice and future studies.
KAYNAKLAR
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. [Crossref]  [PubMed] 
  2. Tavassoli FA, Devilee P. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. World Health Organization Classification of Tumors. 1st ed. Lyon: International Agency for Research on Cancer (IARC); 2003.
  3. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9):1046-1052. [Crossref]  [PubMed]  [PMC] 
  4. Cadoo KA, McArdle O, O'Shea AM, Power CP, Hennessy BT. Management of unusual histological types of breast cancer. Oncologist. 2012;17(9):1135-1145. [Crossref]  [PubMed]  [PMC] 
  5. Coates AS, Winer EP, Goldhirsch A, et al; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-1546. [Crossref]  [PubMed]  [PMC] 
  6. Wolff AC, Hammond ME, Hicks DG, et al; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-256. [Crossref]  [PubMed]  [PMC] 
  7. Louwman MW, Vriezen M, van Beek MW, et al. Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer. 2007;121(1):127-135. [Crossref]  [PubMed] 
  8. Gokce H, Durak MG, Akin MM, et al. Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma. Breast J. 2013;19(4):374-381. [Crossref]  [PubMed] 
  9. Chen L, Fan Y, Lang RG, et al. Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases. Int J Surg Pathol. 2008;16(2):155-163. [Crossref]  [PubMed] 
  10. Liu XY, Jiang YZ, Liu YR, Zuo WJ, Shao ZM. Clinicopathological characteristics and survival outcomes of invasive cribriform carcinoma of breast: a SEER population-based study. Medicine (Baltimore). 2015;94(31):e1309. [Crossref]  [PubMed]  [PMC] 
  11. Colleoni M, Russo L, Dellapasqua S. Adjuvant therapies for special types of breast cancer. Breast. 2011;20 Suppl 3:S153-S157. [Crossref]  [PubMed] 
  12. Komenaka IK, El-Tamer MB, Troxel A, et al. Pure mucinous carcinoma of the breast. Am J Surg. 2004;187(4):528-532. [Crossref]  [PubMed] 
  13. NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines, Breast Cancer v6.2020. (Accessed December 05, 2020) [Link] 
  14. Grabowski J, Salzstein SL, Sadler GR, Blair S. Intracystic papillary carcinoma: a review of 917 cases. Cancer. 2008;113(5):916-920. [Crossref]  [PubMed]  [PMC] 
  15. Rakha EA, Gandhi N, Climent F, et al. Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. Am J Surg Pathol. 2011;35(8):1093-1103. [Crossref]  [PubMed] 
  16. Lefkowitz M, Lefkowitz W, Wargotz ES. Intraductal (intracystic) papillary carcinoma of the breast and its variants: a clinicopathological study of 77 cases. Hum Pathol. 1994;25(8):802-809. [Crossref]  [PubMed] 
  17. Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99-104. [Crossref]  [PubMed] 
  18. Javid SH, Smith BL, Mayer E, et al. Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg. 2009;197(5):674-677. [Crossref]  [PubMed] 
  19. Günhan-Bilgen I, Oktay A. Tubular carcinoma of the breast: mammographic, sonographic, clinical and pathologic findings. Eur J Radiol. 2007;61(1):158-162. [Crossref]  [PubMed] 
  20. Oakley GJ 3rd, Tubbs RR, Crowe J, et al. HER-2 amplification in tubular carcinoma of the breast. Am J Clin Pathol. 2006;126(1):55-58. [Crossref]  [PubMed] 
  21. Vranic S, Tawfik O, Palazzo J, et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol. 2010;23(5):644-653. [Crossref]  [PubMed] 
  22. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166-173. [Crossref]  [PubMed] 
  23. Al Sayed AD, El Weshi AN, Tulbah AM, Rahal MM, Ezzat AA. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol. 2006;45(2): 188-195. [Crossref]  [PubMed] 
  24. Rakha EA, Coimbra ND, Hodi Z, Juneinah E, Ellis IO, Lee AH. Immunoprofile of metaplastic carcinomas of the breast. Histopathology. 2017;70(6):975-985. [Crossref]  [PubMed] 
  25. Jung SY, Kim HY, Nam BH, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010;120(3):627-637. [Crossref]  [PubMed] 
  26. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413-419. [Crossref]  [PubMed] 
  27. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res. 2000;6(3):782-789. [PubMed] 
  28. Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9(2):R24. [Crossref]  [PubMed]  [PMC] 
  29. Work ME, Andrulis IL, John EM, et al. Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. Breast Cancer Res Treat. 2012;134(3):1209-1220. [Crossref]  [PubMed]  [PMC] 
  30. Chu Z, Lin H, Liang X, et al. Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases. PLoS One. 2014;9(11):e111493. [Crossref]  [PubMed]  [PMC]